At the news
? BULLISHIMPACT 8/10 8-K filed Mar 5, 2026 at 07:35 ET
Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8% YoY growth, 10% organic growth) and GAAP EPS of $0.21, reversing a prior-year loss. The company achieved $38M in operating cash flow (97% increase) and issued 2026 guidance projecting $600-610M revenue and $0.73-0.77 Adjusted EPS, indicating continued growth momentum.
- Q4 revenue: $157.9M (+2.8% YoY, +10% organic)
- Q4 GAAP EPS: $0.21 (vs. $0.00 prior year)
- Q4 cash from operations: $38M (+97% YoY)
- 2026 guidance: $600-610M revenue (+6-7%), $0.73-0.77 Adjusted EPS (+7-13%)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access